The P30 Clinical Studies/Outcomes Core will perform a vital role in coordinating the clinical research activities of the investigators that have independent research related to cystic fibrosis. Moreover the Core will provide the infrastructure for pre-clinical studies and clinical trials to investigate pathogenesis and evaluate new genetic and pharmacotherapies to treat Cystic Fibrosis. The Core's mission will be to support and maintain an analytical lab which supports state-of-the-art multiplex cytokine analyses and other inflammatory indices, a sample repository including sputum, bronchoalveolar lavage (BAL) fluid, and serum, staff trained in physiological measures including nasal potential difference and mucociliary clearance, and lastly statistics support. The Specific Objectives of the Clinical Studies/Outcomes Core will be: 1. To perform specific analytical assays for projects supported by P30 related investigators. 2. Provide the infrastructure to routinely perform physiological outcome measures as endpoints in clinical trials, including mucociliary clearance/airway surface volume scans. 3. Provide infrastructure in biostatistics to support the development of novel investigator-initiated research in CF as well as to validate physiological outcome measures in Aim 2 as endpoints. 4. To maintain a sample bank including serum and sputum from CF patients participating in investigator-initiated and Therapeutic Development Network research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK072506-04
Application #
7675974
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
4
Fiscal Year
2008
Total Cost
$274,341
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Woodcock, Chen-Shan Chen; Huang, Yi; Woodcock, Steven R et al. (2018) Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. J Biol Chem 293:1120-1137
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131:
McAleer, Jeremy P; Kolls, Jay K (2018) Contributions of the intestinal microbiome in lung immunity. Eur J Immunol 48:39-49
Dar, Haider H; Tyurina, Yulia Y; Mikulska-Ruminska, Karolina et al. (2018) Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. J Clin Invest 128:4639-4653
Pradhan-Sundd, Tirthadipa; Vats, Ravi; Russell, Jacquelyn O et al. (2018) Dysregulated Bile Transporters and Impaired Tight Junctions During Chronic Liver Injury in Mice. Gastroenterology 155:1218-1232.e24
Hvorecny, Kelli L; Dolben, Emily; Moreau-Marquis, Sophie et al. (2018) An epoxide hydrolase secreted by Pseudomonas aeruginosa decreases mucociliary transport and hinders bacterial clearance from the lung. Am J Physiol Lung Cell Mol Physiol 314:L150-L156
Saydmohammed, Manush; Yagi, Hisato; Calderon, Michael et al. (2018) Vertebrate myosin 1d regulates left-right organizer morphogenesis and laterality. Nat Commun 9:3381
Caves, Elizabeth A; Cook, Sarah A; Lee, Nara et al. (2018) Air-Liquid Interface Method To Study Epstein-Barr Virus Pathogenesis in Nasopharyngeal Epithelial Cells. mSphere 3:
Perkins, Lydia A; Fisher, Gregory W; Naganbabu, Matharishwan et al. (2018) High-Content Surface and Total Expression siRNA Kinase Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance F508del-CFTR Rescue. Mol Pharm 15:759-767
Qu, Yanyan; Olonisakin, Tolani; Bain, William et al. (2018) Thrombospondin-1 protects against pathogen-induced lung injury by limiting extracellular matrix proteolysis. JCI Insight 3:

Showing the most recent 10 out of 146 publications